In a further push into the speciality pharmaceutical sector, Mallinckrodt has agreed to acquire Questcor Pharmaceuticals and its key commercial product H.P. Acthar® Gel (repository corticotropin injection) for approximately US$5.6 B. Acthar, which has been approved by the US FDA for 19 diverse indications that have an inflammatory component, generated sales of US$761 M in 2013, up 50% on the previous year. Controversy surrounds Questcor, however, with the company facing criticism for its aggressive pricing policy and its promotional practices being the subject of an enquiry by the US Department of Justice.